Research programme: MRGPRX2 inhibitors - Enanta Pharmaceuticals
Latest Information Update: 16 Jan 2026
At a glance
- Originator Enanta Pharmaceuticals
- Class Skin disorder therapies; Small molecules
- Mechanism of Action MRGPRX2 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis; Chronic urticaria
Most Recent Events
- 08 Jan 2026 Preclinical trials in Atopic dermatitis in USA (PO) (Enanta Pharmaceuticals pipeline, January 2026)
- 08 Jan 2026 Preclinical trials in Chronic-urticaria in USA (PO) before January 2026 (Enanta Pharmaceuticals pipeline, January 2026)
- 08 Jan 2026 Pharmacodynamics data from a preclinical trials in Atopic dermatitis and Chronic urticaria released by Enanta Pharmaceuticals